Business Daily Media

Men's Weekly

.

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

  • Written by PR Newswire
Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

- Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) of Australia for the indication of glabellar lines

- First shipment and local launch planned for Q1 2023...Plans to cooperate with major chain clinics and key opinion leaders

SEOUL, South Korea, Nov. 24, 2022 /PRNewswire/ -- Hugel, a global total medical aesthetics company (CEO: Ji-hoon Sohn), announced on November 24th that they obtained marketing approval for 50 and 100 units of its botulinum toxin called 'Letybo' for the indication of glabellar lines from the Therapeutic Goods Administration (TGA) of Australia on the 23rd (local time).

Australia is one of the top 10 countries for aesthetic procedures. Botulinum toxin accounts for the largest proportion (41%) as a non-surgical aesthetic procedure, and the per capita treatment rate is known to be higher than that of the United States. The market size is estimated to be about KRW100bn as of 2022, and it is evaluated as a high potential market with annual growth of about 7% by 2025.

Hugel plans to complete the first shipment and launch in the local market within the first quarter of 2023. The local subsidiary will be in charge of distribution and marketing.

Hugel plans to implement aggressive sales and marketing activities to successfully settle into the Australian market and expand its market share. Moreover, in addition to reasonable pricing, Hugel plans to effectively deliver the efficacy and safety of Letybo by providing training for local medical staff and conducting academic programs in cooperation with major chain clinics and key opinion leaders.

Hugel's CEO, Ji-hoon Sohn, said, "With the marketing approval in Australia, Hugel was able to break new ground, going beyond the Asian, European, and North American markets to enter Oceania. Hugel, the first Korean botulinum toxin company to obtain the marketing approval in Australia, will strive to become a leader in the global botulinum toxin market beyond the leading company in Korea."

View original content to download multimedia:https://www.prnewswire.com/news-releases/hugels-letybo-first-in-korea-to-obtain-marketing-approval-from-australia-301686683.html[1]

Read more https://www.prnasia.com/story/archive/3946390_CN46390_0

Small-Business Cash-Flow Playbook 2025

An educational guide to managing ATO debt, real-time super and growth finance in Australia’s new landscape Why ATO debt just became the most expe...

Landowners Offered $30,000 Per Year for Just 1 Hectare: The Rise of 5MW Battery Projects Across Australia

In a pivotal shift reshaping Australia’s renewable energy landscape, landowners in Queensland, New South Wales, and Victoria are being offered up ...

Major national security tech alliance launches with Aerologix a founding member

Australia’s leading drone intelligence pioneer bolsters sovereign tech power Australia’s leading aerial data and drone intelligence platform, Aer...

Chris Hancock AM Honoured as 2025 Communications Ambassador

SYDNEY Chris Hancock AM, former CEO of AARNet, has been awarded the prestigious Communications Ambassador title at the 2025 Telecommunications Indus...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Sell by LayBy